Fulcrum therapeutics announces recent business highlights and financial results for second quarter 2023

― screening closed for the phase 3 reach pivotal trial of losmapimod in facioscapulohumeral muscular dystrophy (fshd) ―

FULC Ratings Summary

FULC Quant Ranking